150 patients were treated with ceftibuten.

Symptom was the most frequently reported adverse consequence in both the ceftibuten (3%) and cefaclor (3%) groups.
For the communication of adults with AECB, Bensch and associates compared the efficacy of ceftibuten with that of ciprofloxacin.
A totality of 150 patients were treated with ceftibuten, 400 mg/d, and 153 patients received ciprofloxacin, 500 mg bid.
Microbiologic eradication was reported in 90% and 91% of patients in the ceftibuten and ciprofloxacin groups, respectively.
Work-clothing clinical succeeder occurred in 79% of the ceftibuten-treated unit and 84% of the ciprofloxacin-treated building block.
The most common adverse events reported in the ceftibuten and ciprofloxacin groups were sickness (4% in both groups), diarrhea (4% in both groups), and head ache (5% and 3%, respectively).
A randomized, single-blind alikeness of ceftibuten (400 mg/d) with clarithromycin (500 mg bid) in the intervention of AECB in adults demonstrated clinical winner rates of 84% and 87%, respectively.
The two agents had similar microbial eradication rates for H influenzae, M catarrhalis, S pneumoniae, and Haemophilus parainfluenzae. The most common adverse result reported by patients in both intervention groups was worry.
Practitioners must evaluate these comparisons while realizing that there are wide geographic differences in status to antimicrobial agents among gram-negative organisms as well as in the ratio of PR-SP.
However, course collection regarding LRTI in adults indicates that clinicians can have at least as much assurance in once-daily ceftibuten as in thrice-daily cefaclor, twice-daily ciprofloxacin, clarithromycin, or cefuroxime.
UTIs
TMP-SMX is usually one of the first-line agents prescribed for uncomplicated UTIs.
However, action to this compounding has led to increased pursuit in alternative therapy choices.
Ceftibuten is a reasonable soul because of its inhibitory body process against many organisms that lawsuit UTIs, including E coli (Table II).
In an open, noncomparative absorption, Mug and associates treated 68 women with uncomplicated UTIs with ceftibuten, 400 mg/d for 7 days.

Reevaluation of these children 5 to 9 days after cessation of therapy revealed successful clinical finish in 98% of ceftibuten-treated patients and in 96% of TMP-SMX-treated patients.
Only 2 ceftibuten recipients reported adverse effects, 1 with mild gastroenteritis and 1 with mild erythematous rash.
This is a part of article 150 patients were treated with ceftibuten. Taken from "Ceclor Cefaclor Info" Information Blog